compound introduction
YM-53601抑制大鼠肝微粒体和人HepG2细胞中的角鲨烯合成酶活性。YM-53601还可以抑制胆固醇的生物合成（ED | 50 | = 32 mg / kg），从而降低血浆中的胆固醇和甘油三酸酯水平。诸如YM-53601之类的化合物的降脂特性使它们成为替代HMG-CoA还原酶抑制剂/贝特类药物治疗替代品的有趣研究机会。 YM-53601 inhibits squalene synthetase activity in rat hepatic microsomes and human HepG2 cells. YM-53601 can also inhibit cholesterol biosynthesis (ED|50|= 32 mg/kg), causing a reduction in both cholesterol and triglyceride levels in plasma. The lipid-lowering properties of compounds such as YM-53601 make them interesting research opportunities for alternatives to combination HMG-CoA reductase inhibitor/fibrate therapy.
